← Back to Search

Antibiotic

Rifaximin for Monoclonal Gammopathy

Phase 1
Recruiting
Led By Madhav Dhodapkar, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of monoclonal gammopathy of undetermined significance based on International Myeloma Working Group (IMWG) criteria
Clinical diagnosis of monoclonal gammopathy of undetermined significance based on International Myeloma Working Group (IMWG) criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 weeks after study start
Awards & highlights

Study Summary

This trial is testing how well rifaximin works to treat patients with monoclonal gammopathy by reducing the abnormal protein or cells in patients.

Who is the study for?
This trial is for individuals with monoclonal gammopathy, a condition where abnormal proteins are produced by the immune system. Participants must understand and sign consent, not have received antibiotics in the last 3 weeks or be on other investigational treatments for gammopathy. Women of childbearing potential and men must use contraception during and after the trial.Check my eligibility
What is being tested?
The study is testing rifaximin, an antibiotic thought to reduce bacteria in the intestines that may be linked to monoclonal gammopathy. The goal is to see if it can decrease abnormal proteins or cells associated with this condition.See study design
What are the potential side effects?
Rifaximin could cause side effects like digestive issues (nausea, bloating), allergic reactions in those sensitive to its components, headaches, dizziness, fatigue, and changes in blood tests related to liver function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a blood condition called MGUS.
Select...
I have been diagnosed with a blood condition called MGUS.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 weeks after study start
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 weeks after study start for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical response rate defined as a reduction in clonal immunoglobulin (Ig) by > 25%
Secondary outcome measures
Changes in gammopathy
Changes in stool microbiota
Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Side effects data

From 2014 Phase 4 trial • 222 Patients • NCT01842581
19%
Hepatic encephalopathy
17%
Oedema peripheral
16%
Constipation
14%
Nausea
14%
Fatigue
12%
Insomnia
11%
Urinary tract infection
10%
Pruritus generalised
8%
Muscle spasms
7%
Abdominal pain
7%
Decreased appetite
6%
Ascites
6%
Dyspnoea
6%
Headache
5%
Cough
5%
Renal failure acute
5%
Vomiting
5%
Asthenia
5%
Anaemia
5%
Anxiety
4%
Jaundice
4%
Diarrhoea
3%
Abdominal distension
3%
Cellulitis
3%
Depression
2%
Bronchitis
2%
Peritonitis bacterial
2%
Hyperkalaemia
2%
Liver transplant
1%
Acute respiratory failure
1%
Fluid overload
1%
Hyperglycaemia
1%
Gastrointestinal haemorrhage
1%
Non-cardiac chest pain
1%
Haematemesis
1%
Herpes zoster
1%
Cerebrovascular accident
1%
Thrombocytopenia
1%
Pneumococcal bacteraemia
1%
Pneumonia
1%
Sepsis
1%
Septic shock
1%
Craniocerebral injury
1%
Hepatic failure
1%
Hepatitis
1%
Hepatorenal syndrome
1%
Toxic encephalopathy
1%
Subarachnoid haemorrhage
1%
Anxiety disorder
1%
Suicidal ideation
1%
Calculus ureteric
1%
Oliguria
1%
Renal failure
1%
Pleural effusion
1%
Flatulence
1%
Cardiac failure congestive
1%
Haematochezia
1%
Upper gastrointestinal haemorrhage
1%
Chest pain
1%
Systemic inflammatory response syndrome
1%
Chronic hepatic failure
1%
Subdural haematoma
1%
Dehydration
1%
Alcoholic seizure
1%
Hypovolaemic shock
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rifaximin 550 mg BID
Rifaximin 550 mg BID + Lactulose

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (rifaximin)Experimental Treatment1 Intervention
Patients receive rifaximin PO TID on days 1-14 in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rifaximin
FDA approved

Find a Location

Who is running the clinical trial?

The Leukemia and Lymphoma SocietyOTHER
80 Previous Clinical Trials
16,926 Total Patients Enrolled
1 Trials studying Monoclonal Gammopathy
42 Patients Enrolled for Monoclonal Gammopathy
Emory UniversityLead Sponsor
1,632 Previous Clinical Trials
2,556,429 Total Patients Enrolled
Madhav Dhodapkar, MDPrincipal Investigator - Emory University
Emory University Hospital, Emory University Hospital Midtown
All India Inst Of Medical Sci (Medical School)
Mayo Grad School Med/Mayo Fndn (Residency)
4 Previous Clinical Trials
390 Total Patients Enrolled

Media Library

Monoclonal Gammopathy Research Study Groups: Treatment (rifaximin)
Monoclonal Gammopathy Clinical Trial 2023: Rifaximin Highlights & Side Effects. Trial Name: NCT03820817 — Phase 1
Rifaximin (Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03820817 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Indiana
How old are they?
65+
What site did they apply to?
Emory University Hospital/Winship Cancer Institute
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Most responsive sites:
  1. Emory University Hospital/Winship Cancer Institute: < 48 hours
Typically responds via
Email
Average response time
  • < 2 Days
~12 spots leftby Nov 2025